SCHEMBL18220190

SCHEMBL18220190

COCCNC(=O)/C(C#N)=C/c1ccc(-c2ccc3cc(NCCN4CCOCC4)ccc3c2)n1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
KMT2A Q03164 6/20 0.48
KDM4E B2RXH2 4/20 0.48
MAPT P10636 4/20 0.48
HPGD P15428 3/20 0.48
MEN1 O00255 3/20 0.48
GAA P10253 2/20 0.48
HTT P42858 2/20 0.48
USP2 O75604 1/20 0.48
LMNA P02545 5/20 0.46
TDP1 Q9NUW8 1/20 0.43
MAPK1 P28482 2/20 0.42
MITF O75030 1/20 0.42
MDM2 Q00987 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PKM P14618 1/20 0.41
NPC1 O15118 2/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25610124 0.92 KMT2A (0.49) ALDH1A1KMT2AKDM4EMAPTHPGD
SCHEMBL18220217 0.87 KMT2A (0.45) ALDH1A1KMT2AKDM4EMAPTHPGD
SCHEMBL17120798 0.87 KMT2A (0.44) ALDH1A1KMT2AKDM4EMAPTMEN1
SCHEMBL18220186 0.87 CA1 (0.37) ALDH1A1KMT2AKDM4EMAPTHPGD
SCHEMBL18220192 0.86 KMT2A (0.55) ALDH1A1KMT2AKDM4EMAPTHPGD
SCHEMBL18219857 0.86 KMT2A (0.60) ALDH1A1KMT2AKDM4EMAPTHPGD
SCHEMBL18220167 0.85 ALDH1A1 (0.48) ALDH1A1KMT2AKDM4EMAPTHPGD
SCHEMBL18220134 0.85 ALDH1A1 (0.63) ALDH1A1KMT2AKDM4EMAPTHPGD
SCHEMBL25610126 0.84 POLB (0.39) ALDH1A1KMT2AKDM4EHPGDGAA
SCHEMBL25610119 0.84 KMT2A (0.41) ALDH1A1KMT2AMAPTMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10934264-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-03-02 US disclosed
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-04-23 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 ALDH1A1 4151/4885KMT2A 4649/4885KDM4E 4807/4885
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 ALDH1A1 4151/4885KMT2A 4649/4885KDM4E 4807/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 ALDH1A1 4151/4885KMT2A 4649/4885KDM4E 4807/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA ALDH1A1 4226/4885KMT2A 4621/4885KDM4E 4804/4885
US-10934264-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 ALDH1A1 4151/4885KMT2A 4649/4885KDM4E 4807/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA ALDH1A1 4226/4885KMT2A 4621/4885KDM4E 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.